Seattle Genetics and Takeda announced long-term overall survival (OS) data on Adcetris (brentuximab vedotin) from a Phase 2 trial in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Data was presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, CA.
A single-arm clinical trial evaluated patients with relapsed or refractory systemic ALCL (n=58) to assess the efficacy and safety of Adcetris. The trial aimed to also determine duration of response, progression-free survival, and overall survival. A total of 86% of patients achieved an objective response.
Long-term results showed that at a median follow-up of 46.3 months, the estimated four-year survival rate was 64%, with a median overall survival of 55.1 months. The median progression-free survival per investigator was 20 months. Further, 19 of the 38 patients who achieved a complete response remained in remission at the time of last follow-up.
Adcetris is an antibody-drug conjugate directed to CD30, which is expressed in Hodgkin lymphoma and systemic ALCL. It is currently approved for use in the treatment of Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of systemic ALCL after failure of at least one prior multi-agent chemotherapy regimen.